Ricorfotide vedotin

Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) [1][2][3].

Product Specifications

CAS Number

[2082631-84-1]

Product Name Alternative

CBP-1008; LDC 10B

UNSPSC

12352209

Target

Folate Receptor (FR) ; Peptide-Drug Conjugates (PDCs) ; TRP Channel

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cbp-1008.html

Smiles

O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN4C(C(CC4=O)SC[C@H](NC(CC[C@@H](C(O)=O)NC(C5=CC=C(C=C5)NCC(N=C67)=CNC6=NC(N)=NC7=O)=O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC8=CN=CN8)C(N9[C@@H](CCC9)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N%10[C@@H](CCC%10)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC%11=CC=CC=C%11)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)OC)=O

Molecular Formula

C162H243N39O40S

Molecular Weight

3408.97

References & Citations

[1]Fu, et al. Peptide-drug conjugates (PDCs) : a novel trend of research and development on targeted therapy, hype or hope?. Acta pharmaceutica Sinica. B. 2023, 13 (2), 498–516. |[2]Gong, et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023, 41 (16) . |[3]Tan, et al. CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2022. 2022, 82 (12_Suppl) .